- Varda Space Industries raised $251 million in Series D financing.
- The company has now raised approximately $598 million since its 2021 founding.
- Varda is developing orbital manufacturing systems designed to process pharmaceutical materials in microgravity.
- The company says microgravity can enable pharmaceutical crystals and formulations that are difficult to produce on Earth.
- Varda has completed six missions since 2023 and plans more than a dozen additional missions through 2028.
- The company is targeting the development of a pharmaceutical made in space that can eventually be administered to patients on Earth.
Varda Space Industries has raised $251 million in a Series D financing round as the company accelerates efforts to manufacture pharmaceutical products in microgravity and eventually bring space-produced medicines to patients on Earth.
The El Segundo, California-based startup said the latest financing brings its total capital raised to $598 million. The round was led by Lux Capital and Natural Capital, with participation from Founders Fund, Khosla Ventures, Caffeinated Capital, General Catalyst, 8090 Industries, Giant Step and Also Capital. Reuters reported that the financing values Varda at approximately $1.6 billion.
Varda Builds a Pharmaceutical Manufacturing Platform in Orbit
Varda is developing unmanned spacecraft that function as laboratories and manufacturing platforms in low Earth orbit.
The company’s W-Series vehicles carry materials into orbit, where pharmaceutical processing can take place in microgravity before the finished materials are returned to Earth. The approach is based on the idea that the absence of gravity, buoyancy and sedimentation can change how pharmaceutical compounds crystallize.
Varda says these conditions could enable drug formulations with properties that are difficult or impossible to achieve through conventional terrestrial manufacturing.
The company was founded in 2021 by CEO Will Bruey, a former SpaceX engineer, and Founders Fund partner Delian Asparouhov. Its latest financing gives the startup additional capital to move from individual demonstrations toward a more regular manufacturing cadence.
Six Missions Have Already Reached Orbit
Varda launched its first mission in 2023 and has since completed six orbital missions.
The company has used its W-Series capsules to conduct manufacturing and research experiments in microgravity before returning materials to Earth. All but its fourth mission have successfully completed reentry, according to Reuters.
Varda is now planning more than a dozen additional launches and reentries through 2028.
The company is also scheduled to launch two capsules simultaneously for the first time, carrying hypersonic research payloads for government and commercial customers. The launch is planned through a rideshare mission on a SpaceX Falcon 9 rocket.
Microgravity Could Change Pharmaceutical Crystallization
The pharmaceutical opportunity behind Varda’s business is based on the unusual physical environment of orbit.
On Earth, gravity can influence the movement of molecules, fluids and particles during crystallization. In microgravity, those effects are greatly reduced, potentially allowing compounds to form crystals with different structures and greater uniformity.
Varda is seeking to use that environment to produce pharmaceutical materials with characteristics that could potentially improve formulation, purity or drug delivery.
The company says decades of experiments aboard the International Space Station have demonstrated the potential of microgravity for pharmaceutical crystallization. Varda is attempting to turn those research findings into a repeatable commercial manufacturing process.
Pharmaceutical Partnerships Are Becoming a Bigger Focus
Varda’s latest financing will also support the company’s efforts to expand its relationships with pharmaceutical companies.
The startup has been working to establish space-based pharmaceutical processing as part of conventional drug-development programs rather than treating orbital experiments as isolated scientific demonstrations.
In May, Varda and United Therapeutics announced a collaboration focused on manufacturing pharmaceuticals in low Earth orbit. The company has also brought pharmaceutical expertise onto its board, including the appointment of former Pfizer R&D chief Mikael Dolsten.
The involvement of pharmaceutical industry executives and companies reflects Varda’s effort to move closer to producing materials with potential therapeutic applications.
Varda Wants to Move From Experiments to Medicines
The company has set an ambitious long-term goal: producing a pharmaceutical in space that can ultimately be administered to a patient on Earth.
Varda President and co-founder Delian Asparouhov said the company was founded with the expectation that the first product manufactured in space and consumed on Earth would be a pharmaceutical. The new financing, he said, will allow Varda to increase mission frequency and deepen pharmaceutical partnerships.
The company has not yet announced an approved medicine manufactured through its orbital platform. Its current work remains focused on development, processing and demonstrations.
Commercial Scale Remains a Key Challenge
Increasing the frequency of orbital missions is an important part of Varda’s strategy because commercial pharmaceutical manufacturing requires substantially more consistency than one-off research experiments.
The company is therefore working to make launch, in-space processing and reentry increasingly routine.
Varda said it has more than a dozen missions planned through 2028. Reuters also reported that the company has 28 launches booked with different providers for 2027 through 2029, helping reduce its exposure to changes in the launch market.
The ability to reliably return processed pharmaceutical materials to Earth is particularly important because the value of the manufacturing process ultimately depends on materials surviving reentry and being recovered for further development or use.
Government Work Supports Varda’s Expansion
Pharmaceutical manufacturing is not Varda’s only business.
The company also carries government and defense-related payloads, including hypersonic research missions. Reuters reported that roughly 70% of Varda’s payload customer base for the following year is expected to be government-focused, with the remainder coming from commercial pharmaceutical work.
That combination gives Varda multiple potential sources of demand while it develops its pharmaceutical manufacturing business.
The company is also positioning its reentry vehicles as infrastructure for a broader orbital economy, with pharmaceutical processing representing one of the first commercial applications.
The Potential of Microgravity Manufacturing
Space-based manufacturing is attracting growing attention because microgravity can create physical conditions that are difficult to reproduce on Earth. Reduced gravitational effects may influence crystallization, molecular structures, material formation, and other manufacturing processes.
For pharmaceutical research, these conditions could provide scientists with new ways to investigate complex compounds and develop specialized production techniques. Researchers are particularly interested in whether materials produced in orbit can achieve characteristics that are difficult or expensive to obtain through conventional manufacturing.
Building a Commercial Space Manufacturing Platform
The development of commercial manufacturing infrastructure in orbit is an important part of the emerging space economy. Rather than treating orbital missions as individual experiments, companies are working toward repeatable systems that can transport materials into space, conduct manufacturing activities, and safely return products to Earth.
Such infrastructure requires sophisticated spacecraft, automated manufacturing systems, recovery technology, quality controls, and reliable launch services. Scaling these operations will also require improvements in cost efficiency and mission frequency.
Opportunities for the Pharmaceutical Industry
Microgravity manufacturing could eventually become an additional tool for pharmaceutical companies and research organizations. Potential applications include studying protein crystallization, producing specialized materials, and investigating manufacturing processes that behave differently outside Earth’s gravitational environment.
However, successful laboratory results do not automatically translate into commercial products. Developers must demonstrate consistent manufacturing performance, product quality, safety, regulatory compliance, and economic viability before large-scale adoption becomes possible.
A New Intersection of Space and Healthcare
The combination of space technology and pharmaceutical science represents a developing area of innovation. Advances in reusable spacecraft, autonomous systems, launch infrastructure, and orbital platforms are making it increasingly practical to conduct sophisticated manufacturing activities beyond Earth.
